The EPO published Takeda's patent application (EP3552624A1) for a method of treating specific Alzheimer's disease patient subpopulations with pooled immunoglobulin G compositions. The application claims priority and includes detailed IPC classifications covering therapeutic proteins, immunological preparations, and neurological applications. Designated states cover all major European markets including Germany, France, UK, Italy, Spain, and the Nordic countries.

Pharmaceutical companies developing immunoglobin-based therapies should review this patent for potential freedom-to-operate implications. Legal and R&D teams should assess whether their current pipelines or research programs could be affected by Takeda's claimed treatment methods. Patent monitoring services should track this application through the grant process, as the A1 publication indicates substantive examination has been conducted.